Mounjaro Stock Issues in the UK: Separating Rumour from Reality

The biggest misconception: 'Mounjaro is out of stock everywhere in the UK'

This is the myth worth correcting first. Mounjaro is not blanket-unavailable across the UK. What has happened (and the NHS tirzepatide medicines page acknowledges supply pressures on GLP-1 medicines generally) is that specific doses have faced periodic shortfalls, particularly at the 2.5mg and 5mg level. These are the doses people start on, so demand is concentrated there.

The 10mg, 12.5mg and 15mg strengths have, at various points, been more consistently available than the entry-level pens. That's a counterintuitive pattern, but it reflects simple economics: fewer people are titrated to the higher doses at any one time, so the inventory pressure is lower. If you've been told 'Mounjaro is out of stock', it's worth asking whether that applies to your specific prescribed dose or to the pharmacy's entire range.

A second misconception is that buying from an overseas source solves the problem. It doesn't. Medicines purchased outside the UK's licensed supply chain carry serious risks, including counterfeit product, incorrect storage and no clinical oversight. The MHRA's Yellow Card scheme has received reports linked to fake pens bought from unverified sellers. Checking that your pharmacy appears on the GPhC register before you order is the single most important safety step you can take.

Why Mounjaro supply tightened, and what's driving it now

Demand grew faster than Eli Lilly's manufacturing capacity could match. NICE recommended tirzepatide in December 2024 (TA1026), opening an NHS pathway and simultaneously validating private prescribing at scale. The result was a surge in new patients across both routes at the same time. Lilly responded by expanding UK supply agreements, but manufacturing lead times in pharmaceutical production run to months, not weeks, so the gap between demand and availability took time to narrow.

The pricing change from 1 September 2025 added another layer of complexity. As widely reported, Lilly raised the UK list price considerably, with the highest-dose pen moving from roughly £122 to around £330 per four-week supply. Some private providers responded by reducing their stock commitments or adjusting which doses they stock. That shift in the commercial landscape is one reason why availability now varies noticeably between providers, even for the same dose. Our guide to Mounjaro pricing in the UK explains what those cost changes mean in practice.

The good news is that the supply picture has stabilised somewhat compared with the acute shortfalls of late 2024 and early 2025. It has not fully normalised, and isolated dose-level gaps still occur, but the situation is patchy rather than critical.

How a GPhC-registered pharmacy manages stock differently

Not all pharmacies have equivalent access to supply. Pharmacies sourcing directly through Eli Lilly's authorised UK distribution network are better placed to maintain consistent inventory than those buying through secondary wholesalers. GPhC registration is a baseline requirement for any legitimate UK online pharmacy (you can verify any pharmacy by searching the GPhC register at pharmacyregulation.org/registers) but it doesn't automatically guarantee identical stock access.

At nume, our pharmacy (GPhC registration 9012878) works within the licensed UK supply chain. We don't guarantee that every dose is available at every moment (no honest pharmacy can) but when your pen is confirmed and dispatched, it leaves our registered pharmacy the same day (for orders approved before midday, Monday to Friday) and arrives with DPD the next working day in plain, unbranded packaging. Your Mounjaro pen goes straight in the fridge door when it arrives; no trip to a high-street branch required.

If you want to understand what's available for your specific dose right now, the clearest route is to check which Mounjaro doses are currently in stock rather than relying on general 'shortage' reports, which can be months out of date by the time they circulate online. For a broader view of access options, our guide to buying Mounjaro online in the UK covers the steps involved.

What to do if your prescribed dose genuinely isn't available

First, speak to your prescriber, not the internet. A GPhC-registered Independent Prescriber can assess whether staying at your current dose while waiting, temporarily holding supply or adjusting your titration schedule is the right clinical call. That decision belongs to a clinician, not a forum thread.

Second, don't switch pharmacies impulsively. Transferring mid-treatment involves providing evidence of your current dose and treatment history. At nume, transfer patients go through a clinical review before anything is dispensed, that's a patient-safety step, not a bureaucratic one. You can read more about getting Mounjaro stock if you're at the point of looking for a new provider.

Third, be sceptical of social media sellers advertising Mounjaro without a prescription. The MHRA has conducted large-scale enforcement operations targeting counterfeit tirzepatide in the UK, including a raid on an illicit manufacturing site in 2025. The risk is not hypothetical. A pen from an unverified seller may contain the wrong substance, the wrong concentration, or nothing therapeutic at all.

For those wondering about stock at a specific strength (5mg availability in particular has been one of the more volatile points in the market) the most accurate information will always come from a registered pharmacy you've already consulted with, not from third-party stock trackers. If you're thinking about travelling and wondering whether you can buy Mounjaro in Tenerife or another overseas destination instead, our guide explains why that route carries more complications than it might seem. If you're still working out which dose you'd be prescribed, our full Mounjaro guide explains the titration schedule and what to expect at each stage. For a live view of availability across doses and providers, our page covering where Mounjaro is currently in stock is a more reliable starting point than general news reports.